Diabetes Complications Tied to Higher Risk for Gum Disease
By Lori Solomon HealthDay Reporter
THURSDAY, Sept. 19, 2024 -- Neuropathy and retinopathy are positively associated with moderate/severe periodontitis, according to a study published online Aug. 5 in the Journal of Dental Research.
Fernando Valentim Bitencourt, D.D.S., from Aarhus University in Denmark, and colleagues investigated the association between individual and combined diabetic microvascular complications (i.e., neuropathy and retinopathy) and moderate/severe periodontitis. The analysis included 15,922 individuals with type 2 diabetes participating in the Health in Central Denmark study.
The researchers found that in an adjusted analysis, diabetic neuropathy (odds ratio [OR], 1.36) and retinopathy (OR, 1.21) were associated with moderate/severe periodontitis. The coexistence of microvascular complications increased the odds of moderate/severe periodontitis (OR, 1.51). There was an additive effect for modification of dyslipidemia, indicating a positive relative excess risk due to interaction of 0.24 for neuropathy, 0.11 for retinopathy, and 0.44 for both complications. Unmeasured confounders and microvascular complication definitions were ruled out as explanatory factors in a sensitivity analysis. There was an association between diabetic neuropathy and retinopathy, individually and combined, with moderate/severe periodontitis. Dyslipidemia had an additive positive effect modification on diabetic microvascular complications, increasing the odds of moderate/severe periodontitis.
"Dentists should consider recommending a screening for microvascular complications in persons with type 2 diabetes who have moderate/severe periodontitis, especially those with dyslipidemia," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Empagliflozin Has Kidney Protective Effects in Acute Myocardial Infarction
THURSDAY, June 26, 2025 -- Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial...
ADA: Weight Loss, Type 2 Diabetes Remission Up With Replacing Diet Drinks With Water
WEDNESDAY, June 25, 2025 -- For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is associated with greater weight loss...
ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes
WEDNESDAY, June 25, 2025 -- The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.